Danny Tielemans

Danny Tielemans has a diverse work experience spanning over several industries. Danny is currently serving as the Clinical Operations Quality Lead - Director at Argenx since October 2021. In this role, they are responsible for implementing the clinical QMS and maintaining effective internal and external relationships.

Prior to their current position, Danny worked at Bristol-Myers Squibb from September 2018 to September 2021 as the Global Quality Clinical Trials & Systems - Risk Assessments Lead. Here, they focused on risk management, process improvement, and the implementation of predictive analytics.

Danny's extensive experience in quality monitoring and compliance is evident from their role as Director Quality Monitoring and Compliance at The Janssen Pharmaceutical Companies of Johnson & Johnson. Danny held this position from December 2009 to August 2018 and managed the quality activities for infectious diseases and vaccines therapeutic area.

Before joining J&J, Danny served as the Associate Director of Global Clinical Development at Tibotec BVBA from January 2008 to November 2009 and from July 2005 to December 2007.

Their earlier experiences include working as a Quality Assurance Manager at Msource Medical Development, a Clinical Research Associate at CRO Msource Medical Development, and a Scientific Researcher at the Diabetes Research Center, Free University of Brussels. Danny also worked as a Scientific Research Fellow at KU Leuven, Laboratory.

Overall, Danny Tielemans has a strong background in quality management, risk assessments, and clinical trial operations, gained through their extensive work experience in the pharmaceutical industry.

Danny Tielemans received their MSc in Medical Sciences from KU Leuven in the years 1985 to 1987. Prior to that, they completed their MSc in Sciences with a specialization in Biology / Zoology at the KU Leuven from 1981 to 1985.